GlobalData on MSN12 天
FDA approves AbbVie’s Emblaveo for intra-abdominal infections
AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
Pharm Exec11 天
FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...
PMLiVE11 天
AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
pharmaphorum12 天
FDA clears new antibiotic for superbug infections
AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...
FDA approves novel antibiotic EMBLAVEO for cIAI
NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with ...
Pharmabiz12 天
AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra ...
AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...
Contract Pharma12 天
AbbVie’s EMBLAVEO Approved by FDA for Treatment of Complicated Intra-Abdominal Infections
Addresses the significant threat of antimicrobial resistance.